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Dimethylglycine accumulates in uremia and predicts elevated rotic disease [1–3]. Homocysteine is a sulfur amino acid
plasma homocysteine concentrations. product of methionine metabolism that undergoes autox-
Background. Hyperhomocysteinemia is a risk factor for ath-
idation in plasma, producing free radicals that damageerosclerosis that is common in chronic renal failure (CRF), but
endothelial cells and promote low-density lipoproteinits cause is unknown. Homocysteine metabolism is linked to
betaine-homocysteine methyl transferase (BHMT), a zinc metal- oxidation [4–6]. Homocysteine has also been shown to
loenzyme that converts glycine betaine (GB) to N,N dimethyl- enhance platelet aggregation, blood coagulation, and
glycine (DMG). DMG is a known feedback inhibitor of BHMT. vascular smooth muscle growth in vitro [6–8]. Hyperho-We postulated that DMG might accumulate in CRF and con-
mocysteinemia is very common in uremia [9] and is con-tribute to hyperhomocysteinemia by inhibiting BHMT activity.
Methods. Plasma and urine concentrations of GB and DMG sidered to be a factor contributing to the high prevalence
were measured in 33 dialysis patients (15 continuous ambula- of atherosclerotic complications in people with end-stage
tory peritoneal dialysis and 18 hemodialysis), 33 patients with renal disease (ESRD) [2].
CRF, and 33 age-matched controls. Concentrations of fasting
The cause of hyperhomocysteinemia in ESRD has notplasma total homocysteine (tHcy), red cell and serum folate,
been established. Although homocysteine is measurable invitamins B6 and B12, serum zinc, and routine biochemistry were
also measured. Groups were compared, and determinants of urine, renal excretion is a trivial part of its total clearance
plasma tHcy were identified by correlations and stepwise linear [10, 11], and altered metabolism is likely to be much more
regression.
important. The most studied pathways of homocysteineResults. Plasma DMG increased as renal function declined
metabolism are transulfuration, involving cystathionine band was twofold to threefold elevated in dialysis patients.
Plasma GB did not differ between groups. The fractional excre- synthetase, and remethylation by N5,N10-methylenetetra-
tion of GB (FEGB) was increased tenfold, and FEDMG was dou- hydrofolate reductase. An alternate remethylation path-
bled in CRF patients compared with controls. Plasma tHcy
way regulated by betaine-homocysteine methyl transferasecorrelated positively with plasma DMG, the plasma DMG:GB
(BHMT) has received less attention. This zinc-dependentratio, plasma creatinine, and FEGB and negatively with serum
folate, zinc, and plasma GB. In the multiple regression model, enzyme, which is abundant in liver and renal cortex [12, 13],
only plasma creatinine, plasma DMG, or the DMG:GB ratio catalyzes the folate-independent transfer of a methyl
was independent predictors of tHcy. group from N,N,N-trimethylglycine [glycine betaine (GB)]Conclusions. DMG accumulates in CRF and independently
to homocysteine, producing methionine and N,N-dimeth-predicts plasma tHcy concentrations. These findings suggest
ylglycine (DMG; Fig. 1). DMG is a feedback inhibitorthat reduced BHMT activity is important in the pathogenesis
of hyperhomocysteinemia in CRF. of BHMT [14] and is normally excreted in urine or me-
tabolized to sarcosine (Fig. 1) [15]. Whether DMG me-
tabolism is disturbed in chronic renal failure (CRF) is
An elevated plasma total homocysteine (tHcy) con- unknown.
centration is an independent risk factor for atheroscle- The objectives of this study were to determine whether
disturbances in the BHMT pathway are present in CRF
and whether these are associated with hyperhomocys-
Key words: kidney failure, hemodialysis, peritoneal dialysis, glycine
teinemia. Our hypothesis was that plasma DMG concen-betaine, atherosclerosis, hyperhomocysteinemia.
trations might increase in CRF. This would contribute
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Fig. 1. Betaine-homocysteine methyl transferase (BHMT) metabolic pathway: Glycine betaine (GB) is obtained from the diet or by conversion
of dietary choline. BHMT transfers a methyl group from GB to homocysteine, producing methionine and N,N-dimethylglycine betaine (DMG)
that is excreted in urine or metabolized to sarcosine by dimethylglycine dehydrogenase. Abbreviations are: CBS, cystathionine beta-synthetase;
MTHFR, N5,N10-methylenetetrahydrofolate reductase.
METHODS unknown (11%). Group 1 had plasma creatinine concen-
trations of 0.14 to 0.68 mmol/L [calculated creatininePatients
clearance (CCr) 5 8.4 to 55.2 mL/min]. No patients wereThe Canterbury Ethics Committee granted ethical ap-
taking folate supplements. All HD patients took a vita-proval for this study. Ninety-nine subjects (54 males, 95
min supplement containing thiamine 5 mg, riboflavinCaucasian) were enrolled. They were aged 59.5 6 15.9
2 mg, pyridoxine 2 mg, and nicotinamide 20 mg. All(SD) years (range 23 to 86 years) and were divided into
dialysis patients had been on dialysis for more than sixfour groups (Table 1). Group 1 (N 5 33) consisted of
months. Those on HD were receiving five to eight hourspatients with CRF who were not receiving dialysis.
of [mean 7.2 6 1.1 hours (SD)] dialysis at home threeGroup 2 (N 5 33) comprised normal volunteers who
days each week with an acetate buffer, using a 1.1 m2were age and sex matched to group 1. Group 3 (N 5 18)
low-flux polysulfone dialyzer.consisted of patients who were on chronic ambulatory
All patients were seen in a morning clinic after a 14-peritoneal dialysis (CAPD), and group 4 (N 5 15) con-
hour overnight fast. In HD patients, this was alwayssisted of patients on long-term hemodialysis (HD).
before the first dialysis of the week. A history and exami-Patients were excluded if they had suffered any acute
nation were performed to establish whether they hadillness within two weeks.
clinical evidence of vascular disease, and their heightThe diagnoses of the renal patients were chronic glo-
and weight were measured for calculation of body massmerulonephritis (29%), hypertension (15%), reflux ne-
index (BMI). All patients in groups 1 and 2 gave a mid-phropathy (6%), polycystic disease (6%), vasculitis (6%),
stream urine sample. Venous blood was drawn from therenovascular disease (5%), interstitial nephritis (5%),
diabetic nephropathy (3%), other diagnoses (14%), or nonfistula arm for routine biochemistry (Aeroset; Abbott,
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Table 1. Characteristics and blood measurements in all patients (N 5 99)
Controls CRF CAPD HD
(N 5 33) (N 5 33) (N 5 15) (N 5 18)
Age years 69 (53–75) 68 (54–74) 61 (48–67) 50 (36–62)a
Sex male:female 19:14 19:14 8:7 11:7
BMI kg/m2 25.564.8 25.864.4 25.963.3 26.265.9
Homocysteine lmol/L 9.8 (7.6–14.9) 21.0 (18.5–25.7)c 25.5 (16.9–32.6)c 29.7 (25.7–38.2)c
Total protein g/L 76.065.2 74.467.1 70.764.0 75.466.6
RBC folate nmol/L 662 (571–782) 759 (570–837) 987 (734–1107)a 878 (616–1256)
Serum folate nmol/L 17.9 (13.7–24.4) 16.5 (13–21.9) 13.7 (10.7–17.3) 15.3 (12.3–17.6)
Plasma creatinine mmol/L 0.07 (0.06–0.08) 0.25 (0.22–0.38)c 0.89 (0.76–1.02)c 0.83 (0.72–1.17)c
Plasma DMG lmol/L 2.6 (1.8–3.7) 4.8 (3.6–6.2)c 5.4 (3.1–7.2)b 5.6 (4.8–10.1)c
Plasma GB lmol/L 33.6 (23.9–42.1) 32.5 (23.9–42.5) 25.6 (23.4–36.6) 31.9 (28.3–36.2)
Plasma DMG:GB ratio 0.09 (0.06–0.13) 0.13 (0.11–0.20)c 0.15 (0.11–0.24)c 0.17 (0.14–0.30)c
Serum zinc lmol/L 13.562.2 12.061.5b 12.462.7 11.062.3c
Data are median (interquartile range) or mean 6 SD. Abbreviations are: GB, glycine betaine; DMG, N,N-dimethylglycine; BMI, body mass index; RBC, red blood
cell; CRF, chronic renal failure; CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis.
a P , 0.05, b P , 0.005, c P , 0.001 compared to the control group
North Chicago, IL, USA) and hematology (Coulter the derivatizing agent, and a Phenospheret SCX ion-
exchange column was used for the HPLC with a mobilecounter) profiles and to measure the other compounds
phase containing 10.5 mmol/L glycolic acid and 5.2of interest.
mmol/L trimethyl ammonium hydroxide in acetonitrile.
Plasma homocysteine
Folate and vitamin B12Venous blood was collected into chilled ethylenedi-
Serum folate and vitamin B12 concentrations wereaminetetraacetic acid (EDTA) tubes and was centri-
measured by a commercial chemiluminescence assayfuged immediately, and the plasma was frozen at 2208C
(ACS: 180; Chiron Diagnostics, Medfield, MA, USA).until analysis. The plasma tHcy concentration was mea-
Red blood cell folate was calculated from the folatesured within two weeks of collection using a commer-
concentration of a hemolysate of 25 mL whole blood incially available fluorescent polarizing immunoassay
0.5 mL ascorbic acid, using the formula: Folate (rbc) 5method (IMX; Abbott). The assay was subject to regular
[Folate (hemolysate) 3 21] 4 [hematocrit].quality control had an interassay variability (coefficient
of variation) of 4%. Vitamin B6
Pyridoxal-5-phosphate was extracted from heparin-Glycine betaine and dimethylglycine
ized blood with hydrochloric acid and derivatized withBlood was collected into EDTA tubes and separated
semicarbazide. The semicarbazide derivative was sepa-immediately. The separated plasma was stored at 2208C
rated by HPLC with postcolumn adjustment of the eluateuntil analysis. Concentrations for DMG and GB were
to pH 10 and fluorescence monitoring at 365 nm/460 nmmeasured by high-performance liquid chromatography
(Instruchemie, Hilversum, The Netherlands).
(HPLC) using a method adapted from Lever et al [16].
The compounds were extracted into 10% methanol in Serum zinc
acetonitrile and were then derivatized with naphthacyl- A protein-free filtrate was prepared by mixing the
triflate [17]. Separation of the derivatives was performed plasma sample with an equal volume of 10% trichloro-
using HPLC on a 250-4 (5 mm) alumina column (Alus- acetic acid, standing for 10 minutes, and then centrifuged.
phert; Merck, Darmstadt, Germany) and with ultraviolet The supernatant was analyzed for zinc by flame atomic
detection (wavelength 249 nm). The mobile phase con- absorption spectroscopy at 213.9 nm on a Varian AA10
tained 10 mmol/L succinic acid and 3.7 mmol/L triethyl- (Varian Australia Pty Ltd., Springvale, Victoria, Austra-
amine in acetonitrile. Data were integrated using Delta lia) using an air acetylene flame.
for Windows version 5.0 (DataworX Ltd., Brisbane, Aus-
Urine measurementstralia). Standards were used to quantitate HPLC peaks,
and spiked plasma samples were used to determine Urine creatinine concentrations were measured by an
plasma recoveries, which were always over 90%. The autoanalyzer (Aeroset; Abbott), and the urinary concen-
interassay and intra-assay coefficients of variation were trations of DMG and GB were determined by the same
less than 8%. A second HPLC system was used to verify HPLC method used for the plasma samples. The ratio
the DMG results. This system used the same extraction of urine:plasma concentrations was used to estimate the
fractional excretion using this formula:procedure; however, 2-fluorenacyl triflate was used as
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Fig. 3. Plasma DMG:GB ratio and plasma homocysteine (N 5 99, r 5Fig. 2. Plasma DMG and homocysteine concentrations (N 5 99, r 5
0.54, P , 0.001).0.42, P , 0.001).
FEGB (%) 5 (UGB/PGB)/(UCr/PCr) 3 100
where U and P denote urine and plasma concentrations
of GB, DMG or creatinine, respectively. Creatinine clear-
ance (CCr) was calculated for groups 1 and 2 from plasma
creatinine using the Cockroft and Gault formula [18].
Statistics
Measurements in normal controls were compared with
those made in the other groups by independent Student-t
or Mann–Whitney tests, as appropriate. Pearson’s test
was used to determine correlations between plasma tHcy
and the other measured variables. To find independent
predictors of tHcy, all variables that correlated signifi-
cantly with plasma tHcy were entered into a stepwise Fig. 4. Serum zinc and plasma homocysteine concentrations (N 5 99,
r 5 20.31, P 5 0.001).multiple linear regression model. Results with P values
,0.05 were considered statistically significant.
0.001; Fig. 3). Plasma tHcy correlated negatively withRESULTS
serum folate (r 5 20.35, P 5 0.001), zinc (r 5 20.31,
Complete data were obtained for the four patient P 5 0.002; Fig. 4), and plasma GB (r 5 20.25, P 5
groups (Table 1). Compared with controls, patients with 0.015).
renal disease had significantly higher plasma tHcy and Statistical analysis was repeated for the nondialysis
DMG concentrations. Plasma GB concentrations did not patients only (groups 1 and 2). In these 66 patients,
differ significantly between groups. Red blood cell folate similar correlations with plasma tHcy were present, in-
was higher in CAPD patients, but serum folate did not cluding DMG (r 5 0.45, P , 0.001), the plasma
differ between groups. Serum zinc was lower in HD DMG:GB ratio (r 5 0.64, P , 0.001), plasma GB (r 5
patients than in controls. There were no significant differ- 20.28, P 5 0.03), and serum zinc (r 5 20.3, P 5 0.012).
ences between those treated with HD and those receiv- Plasma tHcy correlated negatively with vitamin B6 (r 5
ing CAPD. 20.31, P 5 0.01), but correlations with red cell (r 5
Plasma tHcy correlated positively with plasma creati- 20.1) and serum folate (r 5 20.22) were nonsignificant.
nine (r 5 0.73, P , 0.001), DMG (r 5 0.42, P , 0.001; As CCr decreased, plasma tHcy (r 5 20.71, P , 0.001),
plasma DMG (r 5 20.43, P , 0.001), and the plasmaFig. 2), and the ratio of plasma DMG:GB (r 5 0.54, P ,
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DMG:GB ratio (r 5 20.429, P , 0.001) all tended to before any clinical benefits from homocysteine reduction
will be seen.increase.
Theoretically, dietary supplementation with betaineThe relationships between plasma DMG, the DMG:
might overcome competitive inhibition of dimethylgly-GB ratio, and tHcy were consistent in HD and CAPD
cine on BHMT and reduce tHcy levels. However, twogroups and across all 33 dialysis patients (r 5 0.36, P ,
studies of betaine supplementation in dialysis patients0.05 for DMG:GB). Other correlations, including serum
have failed to show any benefit from betaine administra-zinc (r 5 20.29, P 5 0.15) and serum folate (r 5 20.24,
tion [20, 21]. The reasons for this are not clear. PlasmaP 5 0.2), did not reach statistical significance in these
GB concentrations were not measured in either study,33 patients.
and it is possible that the doses used (4 to 6 g daily)Variables that independently predicted tHcy in the
were inadequate in the face of continued removal of GBstepwise linear regression model were the plasma creati-
by dialysis. Alternatively, there may have been insuffi-nine concentration (R2 5 0.41, partial correlation 5 0.55,
cient clearance of DMG to prevent it from inhibitingP , 0.001) and the plasma DMG concentration (R2 5
BHMT activity. Optimal tHcy lowering therapy may re-0.446, partial correlation 5 0.249, P , 0.05). When the
quire new approaches to overcome DMG feedback inhi-plasma DMG:GB ratio was used instead of DMG (since
bition of BHMT. Possible methods include increasingit is derived from DMG), it was a stronger independent
DMG clearance by longer or more efficient dialysis orpredictor of tHcy (R2 5 0.528, partial correlation 5 0.447,
the addition of GB to dialysate, which might shift theP , 0.001).
equilibrium allowing BHMT to continue transmethyla-Urine DMG was similar in CRF patients and controls
tion of homocysteine.[median 5 6.4 (CRF) vs. 8.2 mmol/mmol creatinine (con-
Studies in experimental animals have shown thattrols), P 5 NS], but urine GB was elevated in the CRF
BHMT activity can be increased by dietary manipula-group (28.4 vs. 9.0 mmol/mmol creatinine, P , 0.001).
tions. Park and Garrow reported that rats fed a diet lowThe FEDMG increased as CCr declined (r 5 20.35, P 5 in methionine had a fourfold increase in BHMT activity,0.005) and was nearly two times higher in CRF patients
and further increases were observed when supplemental
compared with controls (34.1 vs. 20.2%, P , 0.001). The
betaine or choline was added [22]. Conversely, dimethyl-
FEGB increased more markedly with declining CCr (r 5 glycine is available as a dietary supplement in health
20.65, P , 0.001) and was tenfold higher in CRF patients food stores, and there are currently several Internet Web
(28.5 vs. 2.6%, P , 0.001). The FEGB correlated positively sites marketing it for human consumption. Most claim
with plasma tHcy in the univariate analysis (r 5 0.47, that dimethylglycine supplements improve aerobic mus-
P , 0.001). cle activity, immunologic responses, and a variety of neu-
rological disorders. From our results, however, we would
question whether they would be ideal for the cardiovas-DISCUSSION
cular health of people with renal impairment.
We have demonstrated, to our knowledge for the first
This study is limited by its cross-sectional design, and
time, that plasma DMG is elevated in CRF and that it we cannot prove that the associations are causal. The
correlates with homocysteine. Dimethylglycine increased FEGB was markedly increased in those with CRF, and itas renal function declined, but it also predicted tHcy correlated positively with plasma tHcy. This could simply
independent of renal function. The ratio of plasma mean that both are sensitive markers of renal injury.
DMG:GB, which is likely to best reflect the flux through Alternatively, it might suggest reduced tubular GB up-
BHMT, was the strongest predictor of plasma tHcy con- take is a cause or result of decreased renal BHMT activ-
centrations. Serum zinc also correlated inversely with ity. The FEDMG was increased to a much lesser extent,
tHcy in the univariate analysis, which lends further sup- but it is unclear whether the increased plasma levels of
port to the hypothesis that BHMT is an important deter- DMG result primarily from reduced renal clearance or
minant of plasma tHcy concentrations in CRF. from impaired metabolism. Further research is needed
Homocysteine concentrations increase with progres- to elucidate the cause of increased plasma DMG levels,
sive renal failure so that by the time ESRD is reached, and the relationship between disturbed renal GB han-
more than 80% of patients have elevated tHcy levels dling and BHMT activity. To understand better BHMT’s
[9]. Folate-based treatment regimens reduce fasting tHcy role in hyperhomocysteinemia, further studies using in-
by 30 to 50%, but even with doses of 60 mg folate daily, terventions that alter its activity are also needed so that
tHcy concentrations are seldom normalized [19]. Al- effects on plasma tHcy can be determined.
though evidence of benefit from randomized controlled In conclusion, we found that plasma DMG concentra-
trials is lacking, it is widely believed that lowering tHcy tions were increased in patients with CRF, whereas GB
should be a goal in ESRD patients. However, more effec- levels were unchanged. Previous in vitro studies indicate
that such a disturbance would inhibit BHMT activity,tive therapies that can normalize tHcy may be required
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